Health · 33 views
Continuing tirzepatide at full dose helps preserve weight loss over 112 weeks
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times…
Summary
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times more likely to maintain that weight loss by continuing on MTD than those who stop treatment, while those who switch to a lower dose of 5 mg are four times more likely to maintain weight loss than those who stop.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Low-carb diet high in saturated fat shows mixed effects on cholesterol in two-year trialContinue reading
- Congress Mulls Ways to Fix the Surprise Billing LawContinue reading
- Fenebrutinib May Curb Chronic Active Lesions in Multiple SclerosisContinue reading
- How our blood vessels age from withinContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow